We Offer Worldwide Shipping
Login Wishlist

Sodium taurodeoxycholate

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-D1273

  • Specification : 98%(HPLC)

  • CAS number : 1180-95-6

  • Formula : C26H44NNaO6S

  • Molecular Weight : 521.69

  • PUBCHEM ID : 23664773

  • Volume : 20MG

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D1273

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

521.69

Appearance

White crystalline powder

Botanical Source

Structure Type

Category

Standards;Natural Pytochemical;API

SMILES

CC(CCC(=O)NCCS(=O)(=O)[O-])C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C.[Na+]

Synonyms

Ethanesulfonic acid, 2-[[(3α,5β,12α,20R)-3,12-dihydroxy-24-oxocholan-24-yl]amino]-, sodium salt (1:1)/Sodium 2-(((3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl)amino)ethane-1-sulphonate/Sodium 2-{[(3α,5β,12α,20R)-3,12-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonate/Taurodeoxycholate sodium salt/Sodium Taurodeoxycholate/Taurodeoxycholic acid sodiuM salt/Sodium taurodeoxycholate hydrate

IUPAC Name

sodium;2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate

Applications

Taurodeoxycholate sodium salt is a bile salt-related anionic detergent used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) inhibits various inflammatory responses[1] [2][3].

Density

Solubility

Flash Point

Boiling Point

Melting Point

168 °C (dec.)(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2934990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:1180-95-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28657593

Abstract

The focus of the present work was to investigate the interaction of the anticancer drug mitoxantrone with two bile salts, sodium taurodeoxycholate (NaTDC) and sodium taurocholate (NaTC). Ultraviolet-visible (UV-Vis) absorption and electron paramagnetic resonance (EPR) spectroscopy were used to quantify the interaction and to obtain information on the location of mitoxantrone in bile salt micelles. The presence of submicellar concentrations of both bile salts induces mitoxantrone aggregation and the extent of drug aggregation in NaTDC is higher than in NaTC. For micellar bile salts concentrations, mitoxantrone monomers are entrapped in the micellar core. Binding constants, micelle/water partition coefficients and the corresponding thermodynamic parameters for binding and partitioning processes were estimated using the changes in monomer absorbance in the presence of bile salts. Binding interaction of mitoxantrone is stronger for NaTDC than NaTC micelles, whereas partitioning efficiency is higher for NaTC micelles for all investigated temperatures. Thermodynamic parameters indicate that both binding and partitioning processes are spontaneous and entropy controlled. The spectral behavior and thermodynamic parameters indicate distinct types of mitoxantrone interaction with NaTDC and NaTC micelles supported by the differences in nature and structure of bile salts micelles.

KEYWORDS

UV-Vis absorption spectroscopy; bile salts; binding constant; electron paramagnetic resonance spectroscopy; mitoxantrone; partition coefficient

Title

Spectroscopic Investigation of the Interaction of the Anticancer Drug Mitoxantrone with Sodium Taurodeoxycholate (NaTDC) and Sodium Taurocholate (NaTC) Bile Salts.

Author

Enache M1, Toader AM2, Neacsu V3, Ionita G4, Enache MI5.

Publish date

2017 Jun 28

PMID

31215257

Abstract

Taurodeoxycholate (TDCA) inhibits various inflammatory responses suggesting potential clinical application. However, the toxicity of TDCA has not been evaluated in detail in vivo. We investigated the acute toxicity and 4-week repeated-dose toxicity of TDCA following intravenous infusion under Good Laboratory Practice regulations. In the sighting study of acute toxicity, one of two rats (one male and one female) treated with 300 mg/kg TDCA died with hepatotoxicity, suggesting that the approximate 50% lethal dose of TDCA is 300 mg/kg. Edema and discoloration were observed at the injection sites of tails when rats were infused with 150 mg/kg or higher amount of TDCA once. In 4-week repeated-dose toxicity study, no treatment-related mortality or systemic changes in hematology and serum biochemistry, organ weights, gross pathology, or histopathology were observed. However, the tail injection site showed redness, discharge, hardening, and crust formation along with histopathological changes such as ulceration, edema, fibrosis, and thrombosis when rats were infused with 20 mg/kg TDCA. Taken together, TDCA induced no systemic toxicity or macroscopic lesions at the injection site at a dose of 10 mg/kg/day, which is 33 times higher than the median effective dose observed in a mouse sepsis model. These findings suggest that TDCA might have a favorable therapeutic index in clinical applications.

KEYWORDS

Taurodeoxycholate; acute toxicity; bile acid; sepsis; subacute toxicity

Title

Evaluation of acute and subacute toxicity of sodium taurodeoxycholate in rats.

Author

Choi HJ1,2, Yun JW3, Kim YH4, Kwon E2, Hyon MK1,2, Kim JY1,2, Che JH5, Kim WH6, Seong SY4, Kang BC1,2,5,7.

Publish date

2019 Jun 19

PMID

31215246

Abstract

Sodium taurodeoxycholate (TDCA) has been investigated for various inflammatory disorders such as sepsis. We recently evaluated nonclinical safety profile of TDCA using rats infused intravenously. As a series of preclinical safety investigations, we further conducted toxicity studies with TDCA delivered to dogs via intravenous administration under Good Laboratory Practice regulation in this study. In dose range-finding study (dose escalation study), dogs given with TDCA at a dose of 150 mg/kg showed marked changes in clinical signs, hematology, and serum biochemistry. And biochemical markers of liver damage and local skin lesions were observed following intravenous infusion of 100 mg/kg TDCA, suggesting that 100 mg/kg was chosen as the highest dose of TDCA for 4-week repeated-dose toxicity study using dogs. Despite no treatment-related significant changes in body weight, food consumption, ophthalmoscopy, and urinalysis, skin lesions were observed at the injection site of animals administered with higher than 50 mg/kg of TDCA along with biochemical and histopathological changes associated with liver injury. However, most of off-target effects were found to be reversible since these were recovered after stopping TDCA infusion. These findings indicate that the no-observed-adverse-effect-level (NOAEL) for TDCA in dogs was considered to be 5 mg/kg/d. Taken together, our results provide important toxicological profiles regarding the safe dose of TDCA for drug development or clinical application.

KEYWORDS

Taurodeoxycholate; acute toxicity; bile acid; dog; sepsis; subacute toxicity

Title

Nonclinical toxicology studies with sodium taurodeoxycholate: acute and subacute toxicity in dogs.

Author

Choi HJ1,2, Yun JW3, Kim YH4, Kwon E2, Hyon MK1,2, Kim JY1,2, Che JH5, Park JS2, Kim HC6, Kim WH7, Seong SY4, Kang BC1,2,5,8.

Publish date

2019 Jun 19